Physician profile
George E Stamos
NPI 1710971411
$1,612.17
in general payments reported to CMS, 2019-2025
26 companies · $39.15 in 2025
The $39.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $283 · 2021: $292 · 2022: $114 · 2023: $71.25 · 2024: $13.15 · 2025: $39.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.60 | 2019-2020 | |
| Abbvie INC. | $271.90 | 2019-2023 | Ubrelvy |
| Pfizer INC. | $215.33 | 2019-2023 | |
| Novo Nordisk INC | $142.69 | 2019-2023 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.64 | 2019-2020 | |
| Boston Scientific Corporation | $62.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.35 | 2019 | |
| Lilly USA, LLC | $52.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.92 | 2019-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $49.44 | 2022 | |
| Amarin Pharma, INC. | $42.25 | 2020-2022 | |
| Allergan, INC. | $41.43 | 2020 | |
| Radius Health, INC. | $33.70 | 2019-2025 | Tymlos |
| Eisai INC. | $28.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.17 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2019 | |
| Abbott Laboratories | $21.58 | 2021 | |
| Sumitomo Pharma America, INC. | $17.84 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $16.91 | 2019 | |
| Glaxosmithkline, LLC. | $14.92 | 2019 | |
| Genzyme Corporation | $14.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.81 | 2019 | |
| Vivus LLC | $14.73 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.50 | 2021 | |
| Vifor Pharma, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Stamos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.